Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-5670b
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DS-5670b is a monovalent mRNA vaccine developed by Daiichi Sankyo that specifically targets the Omicron BA.4 and BA.5 subvariants of SARS-CoV-2. It utilizes a proprietary lipid nanoparticle (LNP) delivery system to transport mRNA encoding the viral spike protein into host cells. Once inside, the mRNA is translated into the spike protein, which serves as an antigen to stimulate a protective immune response, including the production of neutralizing antibodies and T-cell activation. Approved in Japan in November 2023, it was the first domestically developed mRNA vaccine in Japan to be authorized for use as a booster against the Omicron variant. The vaccine was developed as part of a Japanese government-supported initiative to establish domestic vaccine manufacturing and supply capabilities.
- Brand names
- Daichirona
- Other names
- nafidameran (Omicron BA.4-5)Daiichi Sankyo COVID-19 mRNA vaccine (Omicron BA.4-5)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on DS-5670b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-5670b.